Bharat Parenterals financials

·Pharma & HealthChart ›

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY23Mar 2023FY22Mar 2022
1,105——
6.46.414.8
6.96.99.7
1,105——
218218212
—+2.8%—
21.421.428.1
9.8%9.8%13.3%
15.515.521.5
24.324.321.3
11.2%11.2%10.1%
₹42.14₹42.14₹36.89
—+14.2%—
−11.6−11.6—
−11.6−11.6—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BPLPHARMA₹1,912.90

Bharat Parenterals Limited

· Pharma & Health
₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹1,105 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
Current
last close
Market Capitalization——1,104.7
- Cash, Equiv & ST Investments14.86.46.4
+ Total Debt9.76.96.9
Enterprise Value——1,105.3
Revenue212.0218.0218.0
Growth %, YoY—+2.8—
EBITDA28.121.421.4
Margin %13.289.809.80
EBIT21.515.515.5
Net Income21.324.324.3
Margin %10.0511.1611.16
EPS, Adj (current shares)36.8942.1442.14
Growth %, YoY—+14.2—
Cash from Operations—-11.6-11.6
Free Cash Flow—-11.6-11.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.

Bharat Parenterals financials and key ratios

Figures from the company's filings with NSE

In FY23 its consolidated net profit was ₹24.3 crore on revenue of ₹218 crore.

Bharat Parenterals at a glance · consolidated

Free cash flow (FY23)
−₹11.6 Cr
EPS (FY23)
₹42.14

Questions

What is the Bharat Parenterals EPS?

Bharat Parenterals' basic earnings per share (EPS) were ₹42.14 in FY23, against ₹37.11 in FY22.

What is the Bharat Parenterals dividend in 2026 and its record date?

In 2026, Bharat Parenterals has declared one dividend: ₹1 with record date 12 September 2026 and ex-date 11 September 2026.

What is the Bharat Parenterals free cash flow?

In FY23, Bharat Parenterals generated ₹11.6 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹11.6 crore.

What is the Bharat Parenterals revenue and profit in FY23?

In FY23 (April 2022–March 2023), Bharat Parenterals' consolidated net profit was ₹24.3 crore, up 14.2% from ₹21.3 crore in FY22, on revenue from operations of ₹218 crore (up 2.8%).

Where do these Bharat Parenterals figures come from?

From Bharat Parenterals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.